Company Description
Checkpoint Therapeutics, Inc., a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally.
The company’s lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors.
It is developing Olafertinib, which is in Phase 3 clinical trials for the treatment of adult patients with metastatic non-small cell lung cancer; CK-103 for the treatment of various advanced and metastatic solid tumor cancers; and Anti-Carbonic Anhydrase IX (CAIX) antibody, a product candidate in preclinical trials to recognize CAIX expressing cells and kill them via antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity.
The company has licensing and collaboration agreements with Adimab, LLC for the development of Cosibelimab; NeuPharma, Inc., to develop and commercialize Olafertinib; and Jubilant Biosys Limited for the development and commercialization of novel compounds that inhibit BET bromodomains, as well as collaboration with GC Cell.
The company was incorporated in 2014 and is based in Waltham, Massachusetts. Checkpoint Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc.
| Country | United States |
| Founded | 2014 |
| IPO Date | Jun 26, 2017 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 23 |
| CEO | James Oliviero |
Contact Details
Address: 95 Sawyer Road, Suite 110 Waltham, Massachusetts 02453 United States | |
| Phone | 781 652 4500 |
| Website | checkpointtx.com |
Stock Details
| Ticker Symbol | CKPT |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001651407 |
| CUSIP Number | 162828107 |
| ISIN Number | US1628282063 |
| Employer ID | 47-2568632 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| James F. Oliviero III, C.F.A. | President, Chief Executive Officer and Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 12, 2024 | 10-Q | Quarterly Report |
| Nov 12, 2024 | 8-K | Current Report |
| Oct 1, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Aug 30, 2024 | EFFECT | Notice of Effectiveness |
| Aug 28, 2024 | UPLOAD | Filing |
| Aug 19, 2024 | S-3 | Registration statement under Securities Act of 1933 |
| Aug 12, 2024 | 10-Q | Quarterly Report |
| Aug 12, 2024 | 8-K | Current Report |
| Jul 25, 2024 | 8-K | Current Report |